Patents by Inventor Mukul DALVI

Mukul DALVI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DRY POWDER INHALER
    Publication number: 20160206559
    Abstract: This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose. A method of treating a patient includes administering to a patient a dry powder medicament having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose.
    Type: Application
    Filed: January 20, 2016
    Publication date: July 21, 2016
    Applicant: Teva Branded Pharmaceutical Products R&D, Inc.
    Inventors: Mukul DALVI, Seah Kee TEE
  • Inhalable medicament
    Patent number: 9364540
    Abstract: The present invention provides a solution formulation for inhalation comprising: a liquid phase; an active ingredient containing a carboxylic ester in which the oxygen atom is covalently bound to a quaternary nitrogen-containing heterocycle, dissolved in the liquid phase; and a magnesium or calcium salt, dissolved in the liquid phase. The formulation is particularly suited to pMDIs and nebulizers.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: June 14, 2016
    Assignee: Teva Branded Pharmaceutical Products R&D, Inc.
    Inventors: Mukul Dalvi, Libo Wu
  • INHALABLE MEDICAMENT
    Publication number: 20150190510
    Abstract: The present invention provides a solution formulation for inhalation comprising: a liquid phase; an active ingredient containing a carboxylic ester in which the oxygen atom is covalently bound to a quaternary nitrogen-containing heterocycle, dissolved in the liquid phase; and a magnesium or calcium salt, dissolved in the liquid phase. The formulation is particularly suited to pMDIs and nebulisers.
    Type: Application
    Filed: February 5, 2015
    Publication date: July 9, 2015
    Applicant: Teva Branded Pharmaceutical Products R&D, Inc.
    Inventors: Mukul DALVI, Libo WU
  • Dry powder inhaler
    Patent number: 9066957
    Abstract: This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of salmeterol per actuation is less than 50 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose. A method of treating a patient includes administering to a patient a dry powder medicament having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of salmeterol per actuation is less than 50 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: June 30, 2015
    Assignee: TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC.
    Inventors: Mukul Dalvi, Seah Kee Tee
  • DRY POWDER INHALER
    Publication number: 20150099726
    Abstract: This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of salmeterol per actuation is less than 50 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose. A method of treating a patient includes administering to a patient a dry powder medicament having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of salmeterol per actuation is less than 50 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose.
    Type: Application
    Filed: October 6, 2014
    Publication date: April 9, 2015
    Applicant: Teva Branded Pharmaceutical Products R&D, Inc.
    Inventors: Mukul DALVI, Seah Kee TEE